Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rani Therapeutics Holdings (RANI) EPS (Weighted Average and Diluted) (2021 - 2025)

Rani Therapeutics Holdings has reported EPS (Weighted Average and Diluted) over the past 5 years, most recently at $0.05 for Q4 2025.

  • Quarterly results put EPS (Weighted Average and Diluted) at $0.05 for Q4 2025, up 118.52% from a year ago — trailing twelve months through Dec 2025 was -$0.47 (up 55.66% YoY), and the annual figure for FY2025 was -$0.45, up 57.14%.
  • EPS (Weighted Average and Diluted) for Q4 2025 was $0.05 at Rani Therapeutics Holdings, up from -$0.12 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for RANI hit a ceiling of $0.33 in Q3 2022 and a floor of -$2.21 in Q4 2022.
  • Median EPS (Weighted Average and Diluted) over the past 5 years was -$0.25 (2024), compared with a mean of -$0.25.
  • Peak annual rise in EPS (Weighted Average and Diluted) hit 306.25% in 2022, while the deepest fall reached 718.52% in 2022.
  • Rani Therapeutics Holdings' EPS (Weighted Average and Diluted) stood at -$0.27 in 2021, then crashed by 718.52% to -$2.21 in 2022, then soared by 87.78% to -$0.27 in 2023, then changed by 0.0% to -$0.27 in 2024, then surged by 118.52% to $0.05 in 2025.
  • The last three reported values for EPS (Weighted Average and Diluted) were $0.05 (Q4 2025), -$0.12 (Q3 2025), and -$0.18 (Q2 2025) per Business Quant data.